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Jaundice in non-cirrhotic primary biliary cirrhosis:
the premature ductopenic variant
F P Vleggaar, H R van Buuren, P E Zondervan, F J W ten Kate, W C J Hop, the Dutch
Multicentre PBC study group
Abstract
The clinical and pathological findings of
four females with primary biliary cirrho-
sis (PBC) with an unusual and hitherto not
well recognised course are reported. Pa-
tients suVered severe pruritus and weight
loss with progressive icteric cholestasis
which did not respond to such treatments
as ursodeoxycholic acid and immunosup-
pressives. In all cases liver histology re-
vealed marked bile duct loss without
however significant fibrosis or cirrhosis.
Further diagnostic studies and repeat
biopsies confirmed the absence of liver
cirrhosis as well as other potential causes
of hyperbilirubinaemia. Comparison of
the fibrosis-ductopenia relationship for
our cases with that for a group of 101 non-
cirrhotic PBC patients indicated that in
the former the severity of bile duct loss
relative to the amount of fibrosis was
significantly higher. The proportion of
portal triads containing an interlobular
bile duct was 3%, 4%, 6%, and 10%
compared with 45% (median; range 8.3–
100%) for controls (p<0.001). Three pa-
tients received a liver transplant 6–7 years
after the first manifestation of PBC be-
cause of progressive cholestasis, refractory
pruritus, and weight loss, while the fourth
patient is considering this option. In one
case cirrhosis had developed at the time of
transplantation while the others still had
non-cirrhotic disease. These cases suggest
that cholestatic jaundice in non-cirrhotic
PBC may be secondary to extensive “pre-
mature” or accelerated intrahepatic bile
duct loss. Although the extent of fibrosis
may be limited initially, progression to cir-
rhosis appears to be inevitable in the long
run. Despite intact protein synthesis and
absence of cirrhotic complications, liver
transplantation in the pre-cirrhotic stage
for preventing malnutrition and to im-
prove quality of life should be considered
for these patients.
(Gut 2001;49:276–281)
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Primary biliary cirrhosis (PBC) is a vanishing
bile duct disorder1 of a highly variable, albeit
slowly progressive, nature. Immunologically
mediated destruction of interlobular and septal
bile ducts, resulting in bile duct loss or ductope-
nia, is considered to be one of the main
pathophysiological events leading ultimately to
liver fibrosis and biliary cirrhosis.2 3 The histo-
logical appearance has been divided into four
stages, the last (stage IV) representing true
cirrhosis.4 In general, jaundice is only encoun-
tered in the cirrhotic stage,5 probably as a conse-
quence of both hepatocellular insuYciency and
bile duct loss.
Jaundice in non-cirrhotic PBC is rare. In
contrast with what is observed in the idiopathic
adulthood ductopenia syndrome for example,6
it appears that the degree of intrahepatic bile
duct loss is usually not severe enough to cause
jaundice. Various—mainly extrahepatic—
factors not specifically related to PBC, includ-
ing hyperthyroidism,7 malignant lymphoma,8 9
liver metastases, certain drugs,10 haemoly-
sis,11 12 concomitant autoimmune hepatitis
flares,13 and major bile duct obstruction can
cause jaundice in non-cirrhotic PBC.
We report here on a subgroup of PBC patients
suVering from severe cholestatic icteric disease
for whom no causative extrahepatic or intrahe-
patic factors other than profound ductopenia
could be identified. Remarkably, this was not
associated with histological evidence of cirrhosis
or substantial fibrosis. A histomorphological
study of these cases and a large group of
non-cirrhotic PBC patients was performed to
define the ductopenia-fibrosis relationship and
to test the hypothesis that our cases exhibited
extreme paucity of bile ducts in relation to the
amount of fibrosis.
Cases
PATIENT NO 1
In 1994, a 39 year old Chinese woman
presented with fatigue, pruritus, and jaundice.
Her previous medical history was unremark-
able. There was no history of alcohol or drug
abuse, or familial liver problems. Laboratory
investigations showed cholestatic serum liver
values (table 1), elevated IgM levels, and an
antimitochondrial antibody (AMA) titre of
1:10240. Total serum bilirubin was 78 µmol/l
(normal <18) while albumin, clotting factors,
and platelet count were normal. Other aetio-
logical studies for viral hepatitis, haemochro-
matosis, á1 antitrypsin deficiency, and Wilson’s
disease were negative. A liver biopsy revealed
severe ductopenia (table 2) and non-cirrhotic
(stage II) PBC. Abdominal ultrasound was
normal: smooth liver surface, no collaterals or
ascites, and normal spleen size and portal
venous flow pattern. Subsequent treatment
with ursodeoxycholic acid (UDCA) and later
with prednisone and azathioprine did not result
in improvements in symptoms, serum bilirubin
Abbreviations used in this paper: PBC, primary
biliary cirrhosis; AMA, antimitochondrial antibody;
UDCA, ursodeoxycholic acid.
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level, or other laboratory parameters. Four
years later a second biopsy was taken. At that
time serum bilirubin level was 103 µmol/l.
Serum albumin and clotting factors were
normal but platelets were slightly decreased
(122×109/l, normal 130–340×109/l). Abdomi-
nal ultrasound was normal but slight spleno-
megaly was noted. Histological examination
showed two bile ducts in a total of 26 portal
tracts. The degree of fibrosis had increased sig-
nificantly and the beginning of nodularity of
the liver parenchyma was noted (PBC stage
III). At present, she is considering the possi-
bility of liver transplantation.
PATIENT NO 2
In 1992, a previously healthy 38 year old Cau-
casian woman presented with pruritus and
fatigue. A diagnosis of PBC was made on the
basis of a positive test for AMA (titre 1:10240),
the cholestatic serum liver profile (total bi-
lirubin 34 µmol/l), elevated IgM levels, and
characteristic histology. Studies for viral and
metabolic liver diseases were negative. UDCA
therapy was instituted but did not result in any
improvement in serum liver tests. Treatment
with antipruritics such as cholestyramine,
rifampicin, naltrexone, and oxazepam was
unsuccessful. In 1997, combined prednisone
and azathioprine treatment was given for three
months without amelioration of complaints.
One year later she was referred to the
University Hospital Rotterdam. Jaundice (total
bilirubin 77 µmol/l) and marked cholestatic
serum liver values were found. Histological
examination of the liver showed non-cirrhotic
stage I PBC. In one of 18 portal tracts one bile
duct could be identified (table 2). Severe
pruritus and progressive weight loss (13 kg in
three years) were the main indications for per-
forming liver transplantation 18 months later.
Histological examination of a biopsy specimen
of the liver explant showed PBC stage I with
five intact bile ducts in 32 portal tracts.
PATIENT NO 3
In 1990, a 38 year old Caucasian woman
presented with pruritus and arthralgia. Her pre-
vious medical history was unremarkable. On the
basis of cholestatic serum liver values, elevated
serum IgM levels, positive AMA serology, and
liver biopsy findings a diagnosis of PBC (stage
I–II) was made. Other aetiological studies for
viral and metabolic liver disorders were negative.
During the following five years serum bilirubin
gradually increased from 24 µmol/l in 1992 to 92
µmol/l in 1993 and to 187 µmol/l in 1995. Dur-
ing these years serum albumin, platelets, and
clotting factors were normal. Further liver biop-
sies were taken in 1992 (table 2), 1993, and
1995, all showing ductopenia of increasing
severity but only slight fibrosis. During cholecys-
tectomy in 1993 the liver appeared normal.
Treatment with UDCA and prednisone did not
result in evident symptomatic or biochemical
improvements. Severe fatigue and pruritus
persisted despite treatment with antipruritics
such as cholestyramine, rifampicin, and naltrex-
one. Abdominal ultrasonography and upper
gastrointestinal endoscopy showed no evidence
Table 1 Clinical characteristics and diagnostic findings
Patient No
1 2 3 4
Age (y) 39 43 43 47
Sex F F F F
Ethnic background Chinese Caucasian Caucasian Caucasian
Laboratory values
AMA Positive 1:10240 Positive 1:10240 Positive 1:1280 Negative
M-2 antibody Positive Positive Positive Negative
ANA Positive 1:40 Positive 1:80 Negative Positive 1:640
Total bilirubin (µmol/l; normal <18) 78 77 168 129
APh (U/l; normal <75) 709 926 761 848
ALT (U/l; normal <50) 336 287 56 194
IgG (g/l; normal <15.5) 22.9 14.3 10.6 13.6
IgM (g/l; normal <2.8) 4.07 4.13 4.52 9.19
Bile salts (µmol/l; normal <10) 840 240 400 720
Cholesterol (mmol/l; normal <6.5) 11.3 8.6 32.6 16.0
TSH (mU/l; normal=0.20–4.20) 0.54 0.68 1.23 0.97
LD (U/l; normal <480) 308 345 221 364
Radiology
Endoscopic cholangiography na No stenoses No stenoses No stenoses
Abdominal ultrasonography Normal Normal Normal Normal
Spleen size at US (cm) Not enlarged 9–10 12 15
Visual liver assessment na Normal Normal Normal
Revised AIH score +8 +8 +2 +8
Upper GI endoscopy na No ph No ph No ph
Data obtained at the time of liver biopsy, as indicated in the text.
na, not available; GI, gastrointestinal; ph, portal hypertension; AMA, antimitochondrial antibodies; M-2 antibody, (ELISA test)
antibody directed against the E2 subunit of mitochondrial pyruvate dehydrogenase; ANA, antinuclear antibodies; APh, alkaline
phosphatase; ALT, alanine aminotransferase; IgG, immunoglobulin G; IgM, immunoglobulin M; TSH, thyroid stimulating
hormone; LD, lactate dehydrogenase.
Table 2 Histological findings
Patient No
I II III IV
Biopsy length (mm) 21 28 18 25
Portal tracts (n) 28 18 10 30
Portal tract with interlobular bile duct
(n)
1 1 1 1
Inflammatory bile duct lesion (Y/N) Y N Y N
Bile duct proliferation (0–3) 2 1 1 3
Granulomas (Y/N) Y N N N
Cholestasis (0–3) 0 0 1 1
Cu accumulation (0–3) 1 2 2 2
Portal infiltrate (0–4) 2 1 1 2
Piecemeal necrosis (0–4) 2 1 0 1
Fibrosis (0–4) 2 1 1 3
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of cirrhosis or portal hypertension. She was
referred for transplantation in 1995. The weight
loss was 7 kg when she received a transplant in
1997. The explant showed biliary cirrhosis
(PBC stage IV).
PATIENT NO 4
In 1993, this 47 year old Caucasian was
diagnosed with AMA negative PBC after she
presented with weight loss and pruritus. The
diagnosis was based on serum liver tests indicat-
ing cholestasis, elevated serum IgM levels, and a
liver biopsy showing chronic non-suppurative
destructive cholangitis with portal granulomas.
Other aetiological studies for viral hepatitis,
haemochromatosis, á1 antitrypsin deficiency,
and Wilson’s disease were negative. Pruritus
worsened after institution of treatment with
UDCA and failed to respond to cholestyramine,
rifampicin, and naltrexone. Combination treat-
ment with prednisone and azathioprine was
given for one year without any symptomatic or
biochemical improvement. In February 1998,
shortly after prednisone was discontinued,
severe jaundice (total bilirubin 232 µmol/l) with
aggravating pruritus developed. Serum choles-
terol increased from 8–9 mmol/l to levels as high
as 46 mmol/l while high density lipoprotein
cholesterol decreased to subnormal levels. Peri-
ocular and palmar xanthomatous skin abnor-
malities occurred and her body weight de-
creased from 85 to 55 kg within a period of one
year. In 1999 liver transplantation was per-
formed. The liver explant showed non-cirrhotic
stage II–III PBC with extreme bile duct paucity
(table 2).
Patients and methods
The clinical, biochemical, and histological find-
ings of our cases suggested that in these patients
the course of the disease deviated from “nor-
mal”. Most strikingly, the extent of bile duct loss
seemed to be excessive in relation to the amount
of fibrosis. To substantiate this impression, the
quantified histological findings in our patients
were compared with those of a group of 101
consecutive untreated PBC patients with non-
cirrhotic histology. This population was col-
lected between 1990 and 1998 during a
prospective cohort study of PBC in the Nether-
lands.14 Total serum bilirubin levels in this group
were lower than 23 µmol/l at the time of liver
biopsy. In both our cases and the reference
population, liver specimens were obtained per-
cutaneously using Tru-cut or Menghini 14-16
gauge needles. Biopsies were fixed in formalin
and processed routinely into paraYn blocks.
Sections were stained with haematoxylin and
eosin as well as anticytokeratin 19 antibodies.
The following features of each specimen
were assessed: aggregate length (mm), number
of portal tracts, number of portal tracts with an
interlobular bile duct, degree of fibrosis, and
Ludwig stage.4 The severity of fibrosis was
expressed as a value ranging from 0 to 415 and
from 0 to 5 for biopsies scored between 1990
and March 1994 and between March 1994 and
1998, respectively. The maximum score repre-
sents cirrhosis. The amount of fibrosis was
expressed as a fibrosis score, defined as a
proportion of the maximum score. One biopsy
per patient was included in the statistical
analysis.
The proportion of bile ducts was calculated
by dividing the total number of portal tracts
with an interlobular bile duct by the total
number of portal tracts in each biopsy
specimen. A ductopenic index was calculated
by dividing the total number of portal tracts by
the total number of portal tracts containing an
interlobular bile duct. Thus the higher the
ductopenic index the more serious the loss of
bile ducts. The degree of bile duct loss was also
expressed as biopsy length (mm) divided by the
number of bile ducts.
Figure 1 Scatterplot showing the relationship between
biopsy length and number of portal tracts.
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Figure 2 Scatterplot showing the relationship between the
ductopenic index (ratio of portal tracts (n) to ducts (n))
and fibrosis score. A high index indicates severe ductopenia.
The central line indicates the least squares regression line.
The upper line represents the 97.5 percentile and the lower
line the 2.5 percentile. Note the logarithmically scaled
horizontal axis. Three of four cases fell outside the 95%
reference interval of the control biopsy specimens.
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For the index cases, the possibility of signifi-
cant bile duct obstruction, which could possi-
bly account for the discrepancy between the
clinical features and the non-cirrhotic histol-
ogy, was assessed by means of endoscopic ret-
rograde cholangiography and/or ultrasonogra-
phy. Hyperthyroidism was evaluated by
measurement of serum concentrations of
thyroid stimulating hormone. To exclude con-
comitant autoimmune hepatitis, the revised
international score16 was calculated. Haemoly-
sis was assessed by serum lactate dehydroge-
nase and haematological indices. Abdominal
ultrasound with measurement of spleen size,
upper gastrointestinal endoscopy for detection
of oesophagogastric varices, and visual inspec-
tion of the liver during laparoscopy or
laparotomy were performed to further exclude
the presence of cirrhosis. Statistical analysis
was performed with Stata 4.0 for Windows.
Correlations were calculated using Pearson’s
(r) or Spearman’s (rS) tests. A p level <0.05 was
considered statistically significant.
Results
Clinical, biochemical, histological, and radio-
logical characteristics of the four index patients
are shown in tables 1 and 2. All were females
with a median age of 43 years. The mean age of
the reference group (n=101) was 56 years
(range 37–73); 87% were female and 95% were
AMA positive. Ludwig stages I, II, and III were
found in 20 (20%), 51 (50%), and 30 (30%)
biopsies, respectively.
Median length of the 101 control biopsy
specimens was 16 mm (range 4–40) and the
median number of portal tracts per biopsy was
16 (range 4–44). The median number of portal
tracts/mm of liver tissue was 1.0 (95%
confidence interval 0.98–1.15). The number of
portal tracts correlated well with the aggregate
length of the biopsy core (rS 0.7, p<0.001). The
four cases did not deviate from the pattern
among controls (fig 1).
For our four cases, the proportion of portal
tracts containing normal bile ducts was 3%,
4%, 6%, and 10%, yielding ductopenic indices
of 30, 28, 18, and 10, respectively. For the ref-
erence group, the median proportion of portal
tracts with a bile duct was 45% (range
8.3–100%), significantly diVerent from the
cases (Mann-Whitney test, p<0.001). The
median ductopenic index for the reference
group was 2.2 (range 1–12).
The relationship between the degree of duc-
topenia and fibrosis is shown in fig 2. For the
reference group, the ductopenic index was
positively correlated with the degree of fibrosis
(r=0.51 after logarithmic transformation of the
ductopenic index to obtain normal distribu-
tion; p<0.001). This implies that only 26%
(that is, r2) of the variability in fibrosis may be
attributed to an association with the severity of
ductopenia. Three of four cases fell outside the
95% reference interval (fig 2). Therefore, the
degree of bile duct loss was significantly higher
in our patients, especially when the small
amount of fibrosis was taken into account
(fibrosis score 0.2 in three cases and 0.5 in
one). When the number of bile ducts was
related to biopsy length, instead of the number
of portal tracts, this ratio was significantly
(p<0.001) higher for our cases compared with
controls (fig 3). The extreme ductopenia is
illustrated by a keratin 19 stained biopsy slide
for one of the cases, showing nearly total
absence of pre-existent bile ducts (fig 4).
Other causes that might explain the apparent
discrepancy between the severity of cholestasis
and hyperbilirubinaemia versus the minimal
fibrosis in these PBC patients could not be iden-
tified. In particular, no evidence of hyperthy-
roidism, haemolysis, autoimmune hepatitis
(table 1), previous use of agents known to
induce cholestasis, or major bile duct obstruc-
tion was found. Macroscopic examination of the
liver, performed in three cases, showed normal
livers without evidence of cirrhosis. In addition,
ultrasonography (n=4) and upper gastro-
intestinal endoscopy (n=3) did not reveal signs
of portal hypertension or evidence of other con-
ditions, including cholelithiasis, liver metastases,
or lymphoma. Serum values for albumin and
antithrombin III were within the normal range
in all cases, reflecting intact protein synthesis.
For the three patients who underwent liver
transplantation, the predicted one and two year
survival rates, according to the original Mayo
risk score model (http://www.mayo.edu/int-
med/gi/model/mayomodl-1.htm) at the time of
referral varied from 94% to 97% and from 84%
to 94%, respectively.
Discussion
The cases described in the present report
indicate that among patients with PBC a
subgroup can be identified, characterised clini-
cally by severe cholestasis and histologically by
extreme ductopenia which is not accompanied
by significant liver fibrosis or cirrhosis. The
eVect of medical treatment, including a variety
of antipruretics, UDCA, and immunosuppres-
sives was disappointing. Also, considering the
markedly decreased quality of life of aVected
individuals and the adverse eVect of chronic
severe cholestasis on nutritional status, this pro-
gressive disease evolves in the course of a few
years to the stage where liver transplantation
should be considered. Based on our experience
we believe that the absence of cirrhosis should
not unnecessarily delay transplantation. The
findings for this subgroup are at variance with
the usual course of the disease whereby severe
cholestasis and jaundice are only encountered in
patients with cirrhotic histology.
Histological evaluation of the liver using
needle biopsy may be hampered by the
possibility of sampling error. The accuracy of
diagnosing cirrhosis, and consequently its
absence, by percutaneous needle biopsy alone
has been reported to be poor.17 However, a
combination of this procedure with ultrasonog-
raphy enhances sensitivity to nearly 100%.17 18
Histology was combined with ultrasonography
in our four cases. In addition, in three cases
macroscopic assessment of the liver as well as
upper gastrointestinal endoscopy was per-
formed to further minimise the chances of
missing a diagnosis of cirrhosis.
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Variability in the total size of the biopsy core
influences the yield of portal tracts. The
scatterplot (fig 1) indicates that the biopsies
obtained from our patients were comparable
with those from controls. The data showed that
approximately one portal tract/mm of needle
biopsy tissue was found, confirming the previ-
ously published 1:1 ratio (portal tract: mm
needle biopsy) for the normal adult human
liver.19 Sampling error may also weaken the
data on the severity of ductopenia. In this study
little overlap in degree of ductopenia between
the reference group and our cases was found.
However, the diVerence in degree of bile duct
loss between the case and control groups was
statistically significant, both when the number
of bile ducts was related to the number of por-
tal tracts as well as to the length of the biopsy
specimen. Furthermore, a repeat biopsy in two
of the cases (one non-cirrhotic liver explant)
confirmed the presence of striking ductopenia.
The study allows only speculations on the
aetiopathophysiological diVerences between
patients with the non-cirrhotic severe ductope-
nia variant and those with the more conven-
tional course. We found that the relationship
between ductopenia and fibrosis, although
present, was not very convincing. We hypoth-
esise that in exceptional cases a particularly
aggressive form of immune mediated bile duct
destruction results in extensive ductopenia
within a comparatively short period of time.
The relatively young age of our patients at
presentation with severe cholestasis points to
this possibility. Initially, fibrogenesis seems to
lag behind the rate of bile duct destruction.
Nevertheless, as indicated by the histological
evolution in our patients, progressive fibrosis
eventually does develop.
The mechanism of the frequently observed
hypercholesterolaemia in PBC is incompletely
understood. In two of our patients cholesterol
levels were found to be exceptionally high. A bil-
iary secretion defect due to ductopenia sec may
not satisfactorily explain this finding as the
severe ductopenia of end stage cirrhotic disease
is not associated with cholesterol levels of the
observed magnitude. In the three patients who
were transplanted cholesterol levels normalised
rapidly.
In three of the four reported patients, liver
histological and laboratory examination showed
periportal piecemeal necrosis of slight to moder-
ate severity and the presence of antinuclear anti-
bodies in association with high serum transami-
nase levels. These findings may suggest an
overlap syndrome, in particular with autoim-
mune hepatitis. On the other hand, serum
immunoglobulin G levels were normal or only
slightly elevated and application of the inter-
national autoimmune hepatitis score yielded
scores indicating a very low probability of
autoimmune hepatitis. Finally, immunosuppres-
sive treatment had no beneficial eVect. We
believe that, although some findings are some-
what unusual with respect to “classical” PBC,
there is insuYcient evidence for a PBC-
autoimmune hepatitis overlap syndrome in our
patients.
Previously, Nakanuma et al suggested exten-
sive bile duct loss as a potential cause of choles-
tatic jaundice in non-cirrhotic PBC20 without
however reporting quantitative histological data.
Our study suggests that the proportion of portal
Figure 4 (A) Haematoxylin-eosin coloured liver biopsy from patient No 2 showing at least four portal tracts. The amount
of fibrosis is very limited and there are no portoportal or portoseptal connections. (B) Anticytokeratin 19 (keratin 19)
stained liver biopsy from patient No 2 showing the same portal tracts as in (A) with total absence of pre-existent
interlobular bile ducts and only very moderate ductular proliferation (darkish brown coloured cells).
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tracts with an intact interlobular bile duct has to
be less than 10% in order to produce substantial
hyperbilirubinaemia. Mild ductopenia, defined
as a proportion of portal tracts with an intact
interlobular bile duct >50%, was not shown to
be associated with a rise in serum bilirubin con-
centration in adults with “idiopathic biliary duc-
topenia”.21 Patent bile ducts in 10–50% of portal
tracts, as was found in the large majority of
patients in the reference group, was also not
associated with hyperbilirubinaemia. These per-
centages should not be regarded as absolute
limits but rather as broad indications. Also,
when assessing the degree of ductopenia, the
size of the biopsy specimen should always be
taken into account. For a reliable assessment of
ductopenia a minimum of 20 evaluable portal
tracts has been suggested.22 In clinical practice
however this is not always feasible.
In 1978, Popper hypothesised that in PBC
two pathways may lead to cirrhosis2: one is the
consequence of biliary destruction within the
portal triads and the other is due to periportal
interface hepatitis that is uniformly found in
PBC, albeit to a variable extent. These two
mechanisms may be operative in diVerent
degrees in individual patients. Consequently,
one could speculate that PBC may have a wide
range of phenotypical expressions, varying
from a PBC-autoimmune overlap syndrome on
the one hand to the “premature ductopenic
variant” on the other. Although it appears that
both manifestations eventually may lead to cir-
rhosis, the name of the disease clearly needs to
be revised. “Primary intrahepatic cholangitis”23
may be a more appropriate term.
In conclusion, cholestatic jaundice in non-
cirrhotic PBC may be secondary to an unusu-
ally accelerated intrahepatic bile duct loss.
Although the extent of fibrosis in aVected
patients may be limited initially, progression to
cirrhosis seems to be inevitable. Despite intact
protein synthesis and the absence of cirrhotic
complications, liver transplantation in the pre-
cirrhotic stage for treatment of pruritus and
(prevention of) progressive weight loss due to
malabsorption should be considered. In the
process of decision making the Mayo risk
model does not seem to be a helpful instrument
in this particular subgroup of PBC patients.
We would like to thank Professor V Desmet for studying some
of the biopsy specimens and for critically reviewing the
manuscript.
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